HIV pre-exposure prophylaxis (PrEP)

PrEP is a highly effective strategy that involves an HIV-negative person taking HIV medications on an ongoing basis to reduce the risk of HIV infection. When PrEP is taken as prescribed, HIV transmission is very rare.

Resources

Filter By

Filter By

PrEP/PEP Guideline webinar scrape image

Sep 5, 2024 1:00 pm ET

Previewing Canada’s draft guideline for HIV PrEP and PEP

Research summary

CATIE News 05162024

Study explores preferences for different HIV pre-exposure prophylaxis (PrEP) options in gay, bisexual and other men who have sex with men (gbMSM)

Research summary

CATIE News 05152024

Health Canada approves Apretude, the first long-acting injectable for HIV prevention

Research summary

Article icon

CATIE statement on the use of HIV pre-exposure prophylaxis (PrEP) among people who use drugs

Research summary

CATIE News 02222024

Overcoming barriers to long-acting injectable PrEP

Research summary

CATIE News 02162024

Study with young men underscores the need for long-acting forms of HIV prevention

Research summary

tu-ta-book-img

Safety and effectiveness of long-acting cabotegravir for prevention in cisgender women

Research summary

tu-ta-book-img

Long-acting cabotegravir - focus on transgender women

Research summary

tu-ta-book-img

In context – long-acting cabotegravir for HIV prevention

Research summary

tu-ta-book-img

Major change is coming – long-acting HIV pre-exposure prophylaxis

Research summary

tu-ta-book-img

Learning from a case of breakthrough infection with long-acting cabotegravir for prevention

Research summary

tu-ta-book-img

Safety and effectiveness of long-acting cabotegravir for prevention in men and transgender women